西班牙Cytognos Infinicyt™软件
基本信息
产品名称：
西班牙Cytognos Infinicyt™软件
英文名称：
Infinicyt™软件
国产/进口：
进口
产地/品牌：
西班牙Cytognos
型号：
无
参考报价：
销售商：
总点击数：
1520
更新日期：
2026-04-02
产品类别：
性能参数
五、Infinicyt™软件
Infinicyt™：流式细胞仪数据分析软件
EuroFlow™最初的目标之一是开发新的流式细胞术软件工具，用于识别复杂的免疫表型模式和流式细胞术数据的多元分析。
Infinicyt™软件包括创新的分析、集成和解释工具，使流式细胞术数据分析：多元、标准、高效、灵敏和可重复性
备注：*每次购买或升级Infinicyt™2.0高级许可，以及购买大量、MM MRD和PIDOT工具包，都可以免费访问25个EuroFlow™数据库。
六、文献引用
1. van Dongen, J. J. M. et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26, 1908–1975 (2012).
2. Nguyen, V et al. Customised single tube 14 parameter, 8 colour Lymphoma Screening Panel. In 38th Annual Scientific Meeting Australasian Cytometry Society. Oct 11-14 (2015).
3. Lhermitte, L. et al. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia. Leukemia 32, 874–881 (2018).
4. van Dongen, J. et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125 (26), 3996-4009 (2015).
5. Theunissen, P. et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129, 347–357 (2017).
6. Pérez-Andrés, M. et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 19 (3):449-55 (2005).
7. Flores-Montero, J. et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094–2103 (2017)
8. Paiva B. et al. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125, 3059-3068 (2015).
9. Sanoja-Flores, L. et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer Journal 8 (117) (2018).
10. McEllistrim, C. et al. New developments in the treatment of multiple myeloma – clinical utility of daratumumab. Biologics 11, 31–43. (2017).
11. Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology 17, e328–e346 (2016).
12. Paiva, B. et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood 127, 3165-3174 (2016).
13. Sanoja-Flores, L. et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer Journal 8 (117) (2018).
14. Blanco, E. et al. Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. The Journal of Allergy and Clinical Immunology 141 (6):2208–2219.e16 (2018)
15. Guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies. Draft. European Medicines Agency (26 July 2018) (https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-use-minimal-residual-disease-clinical-endpoint-multiple-myeloma-studies_en.pdf)
16. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment Guidance for Industry. Draft guidance. U.S. Department of Health and Human Services Food and Drug Administration (October 2018). https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM623333.pdf
17. Pedreira, C.E. et al. Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends in Biotechnology 31, (7):415-425 (2013).
18. Novakova, M. et al. How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. Journal of Immunological Methods (2017). https://doi.org/10.1016/j.jim.2017.11.007
更多文献访问;http://www.euroflow.org/usr/pub/publications.php，或拨打010-51668388-8011，QQ:1793915448咨询更多信息。
| 名称 | 货号 |
| InfinicytTM Basic Licence | CYT-INFINICYT-P |
| InfinicytTM Advanced Licence | CYT-INFINICYT-ADV1 |
| InfinicytTM Upgrade | CYT-INFINICYT-AOM |
| EuroFlowTM Database Accesses | CYT-INFINICYT-EFDB |
Infinicyt™：流式细胞仪数据分析软件
EuroFlow™最初的目标之一是开发新的流式细胞术软件工具，用于识别复杂的免疫表型模式和流式细胞术数据的多元分析。
Infinicyt™软件包括创新的分析、集成和解释工具，使流式细胞术数据分析：多元、标准、高效、灵敏和可重复性
备注：*每次购买或升级Infinicyt™2.0高级许可，以及购买大量、MM MRD和PIDOT工具包，都可以免费访问25个EuroFlow™数据库。
六、文献引用
1. van Dongen, J. J. M. et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26, 1908–1975 (2012).
2. Nguyen, V et al. Customised single tube 14 parameter, 8 colour Lymphoma Screening Panel. In 38th Annual Scientific Meeting Australasian Cytometry Society. Oct 11-14 (2015).
3. Lhermitte, L. et al. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia. Leukemia 32, 874–881 (2018).
4. van Dongen, J. et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125 (26), 3996-4009 (2015).
5. Theunissen, P. et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129, 347–357 (2017).
6. Pérez-Andrés, M. et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 19 (3):449-55 (2005).
7. Flores-Montero, J. et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094–2103 (2017)
8. Paiva B. et al. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125, 3059-3068 (2015).
9. Sanoja-Flores, L. et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer Journal 8 (117) (2018).
10. McEllistrim, C. et al. New developments in the treatment of multiple myeloma – clinical utility of daratumumab. Biologics 11, 31–43. (2017).
11. Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology 17, e328–e346 (2016).
12. Paiva, B. et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood 127, 3165-3174 (2016).
13. Sanoja-Flores, L. et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer Journal 8 (117) (2018).
14. Blanco, E. et al. Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. The Journal of Allergy and Clinical Immunology 141 (6):2208–2219.e16 (2018)
15. Guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies. Draft. European Medicines Agency (26 July 2018) (https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-use-minimal-residual-disease-clinical-endpoint-multiple-myeloma-studies_en.pdf)
16. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment Guidance for Industry. Draft guidance. U.S. Department of Health and Human Services Food and Drug Administration (October 2018). https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM623333.pdf
17. Pedreira, C.E. et al. Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends in Biotechnology 31, (7):415-425 (2013).
18. Novakova, M. et al. How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. Journal of Immunological Methods (2017). https://doi.org/10.1016/j.jim.2017.11.007
更多文献访问;http://www.euroflow.org/usr/pub/publications.php，或拨打010-51668388-8011，QQ:1793915448咨询更多信息。
公司简介
普瑞麦迪（北京）实验室技术有限公司坐落于中关村科技园丰台园区，是致力于生命科学实验室整体解决方案的国家高新技术企业。公司秉承“持续创新、以人为本、服务至上、合作共赢”的理念，以“引进全球创新技术、创新产品、助力中国生命科学飞速发展”为使命；聚集了一批行业内的专业精英，包括杰出的留学归国研发和管理人员及国内优秀人才等一起构成公司的精英团队。公司集自主研发和引进国际顶尖技术产品为一体，主营产品涵盖生命科学、医学、环境生物学及化学等领域的高端仪器及试剂。
售后服务
普瑞麦迪公司是专业的流式细胞仪代理和服务商，产品涵盖细胞成像系统、流式细胞仪、分子生物学产品、常规实验室设备及试剂等众多产品。公司有完善的售前、售后、实验室技术团队，有充足的仪器配件、DEMO样机及优秀的技术人员,“服务为本”是普瑞麦迪公司一贯的工作理念。
相关视频
暂无
资料下载
暂无
联系方式
| 单位名称： |
|
详细地址：
北京市丰台区南四环西路188号五区11号楼五层501室
|
|
qq：
|
|
联系电话：
4006-813-863
|
| Email： |
